The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2025 | ASCEND: certepetide & chemotherapy in untreated metastatic pancreatic cancer
Juan Manuel O’Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina, discusses findings from Cohort B of the ASCEND trial (NCT05042128), which evaluated certepetide plus gemcitabine and nab-paclitaxel in previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). Certepetide, a cyclic peptide designed to enhance drug penetration, showed encouraging progression-free survival and response rates compared to placebo, with manageable toxicity. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There are also interesting trials with the ASCEND trial that was a Phase II trial in pancreatic cancer. So there’s very promising data in terms of the median PFS, 7.5 months and also 10 months in overall survival. And the most important is in terms of the overall response rate, 45% in this population. So this is another strategy, another new compound that is the objective of the treatment is to increase the permeability of the chemotherapy and also increase the permeability of the tumor...
There are also interesting trials with the ASCEND trial that was a Phase II trial in pancreatic cancer. So there’s very promising data in terms of the median PFS, 7.5 months and also 10 months in overall survival. And the most important is in terms of the overall response rate, 45% in this population. So this is another strategy, another new compound that is the objective of the treatment is to increase the permeability of the chemotherapy and also increase the permeability of the tumor. So I think for the future, we look again in terms of the biomarker and also more mature data for the future that I think that is interesting to know.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
